<DOC>
	<DOC>NCT02871427</DOC>
	<brief_summary>This study seeks to evaluate the long-term safety and effectiveness of nelotanserin for the treatment of visual hallucinations (VHs) and Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with Lewy body dementia (LBD).</brief_summary>
	<brief_title>Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder</brief_title>
	<detailed_description>This is a multi-center open-label, long-term study in LBD subjects with RBD and/or VHs. Eligible subjects who completed a previous nelotanserin VH or RBD study and choose to participate in this open-label study will receive 20, 40, 60, or 80 mg nelotanserin once daily for 24 weeks.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Hallucinations</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<mesh_term>REM Sleep Behavior Disorder</mesh_term>
	<criteria>Subjects with LBD who completed a previous nelotanserin VH or RBD study Subjects with a current serious and/or unstable cardiovascular, respiratory, thyroid, gastrointestinal, renal, hematologic or other medical disorder</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lewy body dementia</keyword>
	<keyword>Dementia with Lewy bodies</keyword>
	<keyword>Parkinson's disease dementia</keyword>
	<keyword>Visual hallucinations</keyword>
	<keyword>REM sleep behavior disorder</keyword>
</DOC>